Expertise in
12
conditions

Bruno Dubois

Paris, FR 
Expertise in
12
conditions
Paris, FR 

Overview

Bruno Dubois practices practicing medicine in Paris, France.

Mr. Dubois is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Memory Loss, and Developmental Dysphasia Familial.

He is actively involved in clinical research, co-authoring 347 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
Toulouse, France
Bordeaux, France
Nantes, France
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Other
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Enrollment Status: Completed
Publish Date: February 17, 2025
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
Enrollment Status: Terminated
Publish Date: March 31, 2020
View 7 Less Clinical Trials

345 Total Publications

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
Journal: JAMA
Published: July 13, 2026

Frequently Asked Questions about Bruno Dubois

Is Bruno Dubois a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Bruno Dubois is classified as an Elite expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bruno Dubois participate in research or clinical trials?

Yes. Bruno Dubois has published 345 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Bruno Dubois's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dubois's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile